JP2008530984A - 網膜の変性疾患の処置のための改良されたモーダリティー - Google Patents
網膜の変性疾患の処置のための改良されたモーダリティー Download PDFInfo
- Publication number
- JP2008530984A JP2008530984A JP2007552111A JP2007552111A JP2008530984A JP 2008530984 A JP2008530984 A JP 2008530984A JP 2007552111 A JP2007552111 A JP 2007552111A JP 2007552111 A JP2007552111 A JP 2007552111A JP 2008530984 A JP2008530984 A JP 2008530984A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- rpe
- hes
- pigmented
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title description 14
- 210000001525 retina Anatomy 0.000 title description 11
- 208000015122 neurodegenerative disease Diseases 0.000 title description 3
- 210000004027 cell Anatomy 0.000 claims abstract description 477
- 238000000034 method Methods 0.000 claims abstract description 47
- 230000004069 differentiation Effects 0.000 claims abstract description 30
- 102000004142 Trypsin Human genes 0.000 claims abstract description 15
- 108090000631 Trypsin Proteins 0.000 claims abstract description 15
- 239000012588 trypsin Substances 0.000 claims abstract description 15
- 102000029816 Collagenase Human genes 0.000 claims abstract description 12
- 108060005980 Collagenase Proteins 0.000 claims abstract description 12
- 229960002424 collagenase Drugs 0.000 claims abstract description 11
- 108010007093 dispase Proteins 0.000 claims abstract description 8
- 102000004190 Enzymes Human genes 0.000 claims abstract description 7
- 108090000790 Enzymes Proteins 0.000 claims abstract description 7
- 229940088598 enzyme Drugs 0.000 claims abstract description 7
- 238000012258 culturing Methods 0.000 claims abstract description 6
- 210000000653 nervous system Anatomy 0.000 claims abstract description 6
- 230000035755 proliferation Effects 0.000 claims abstract description 6
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 claims abstract description 4
- 239000002609 medium Substances 0.000 claims description 43
- 230000014509 gene expression Effects 0.000 claims description 28
- 102000007354 PAX6 Transcription Factor Human genes 0.000 claims description 23
- 101150081664 PAX6 gene Proteins 0.000 claims description 21
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 16
- 210000002966 serum Anatomy 0.000 claims description 14
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 12
- 239000000049 pigment Substances 0.000 claims description 12
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 11
- 230000012010 growth Effects 0.000 claims description 9
- 108010058237 plasma protein fraction Proteins 0.000 claims description 9
- 229940002993 plasmanate Drugs 0.000 claims description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 8
- 229930182555 Penicillin Natural products 0.000 claims description 8
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 8
- 229940049954 penicillin Drugs 0.000 claims description 8
- 229960005322 streptomycin Drugs 0.000 claims description 8
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims description 6
- 102000008730 Nestin Human genes 0.000 claims description 6
- 108010088225 Nestin Proteins 0.000 claims description 6
- 230000032459 dedifferentiation Effects 0.000 claims description 6
- 210000005055 nestin Anatomy 0.000 claims description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 6
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 claims description 5
- 102000046645 human LIF Human genes 0.000 claims description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- 239000003797 essential amino acid Substances 0.000 claims description 4
- 235000020776 essential amino acid Nutrition 0.000 claims description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 210000001161 mammalian embryo Anatomy 0.000 abstract description 12
- 210000001671 embryonic stem cell Anatomy 0.000 abstract description 11
- 238000002560 therapeutic procedure Methods 0.000 abstract description 10
- 201000007737 Retinal degeneration Diseases 0.000 abstract description 8
- 230000004258 retinal degeneration Effects 0.000 abstract description 8
- 239000000790 retinal pigment Substances 0.000 abstract description 3
- 210000001164 retinal progenitor cell Anatomy 0.000 abstract 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 203
- 108090000623 proteins and genes Proteins 0.000 description 47
- 210000002242 embryoid body Anatomy 0.000 description 40
- 238000002054 transplantation Methods 0.000 description 32
- 108091008695 photoreceptors Proteins 0.000 description 23
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 description 21
- 208000002780 macular degeneration Diseases 0.000 description 19
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 19
- 101710101931 Retinaldehyde-binding protein 1 Proteins 0.000 description 18
- 102100028001 Retinaldehyde-binding protein 1 Human genes 0.000 description 18
- 230000001537 neural effect Effects 0.000 description 18
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 16
- 101150087532 mitF gene Proteins 0.000 description 16
- 210000002569 neuron Anatomy 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 description 15
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 description 15
- 241000282472 Canis lupus familiaris Species 0.000 description 14
- 235000020945 retinal Nutrition 0.000 description 14
- 101000713575 Homo sapiens Tubulin beta-3 chain Proteins 0.000 description 13
- 102100036790 Tubulin beta-3 chain Human genes 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 230000002207 retinal effect Effects 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 239000011604 retinal Substances 0.000 description 12
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 12
- 108050002823 Bestrophin Proteins 0.000 description 11
- 102000012304 Bestrophin Human genes 0.000 description 11
- 101100518992 Mus musculus Pax2 gene Proteins 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 11
- 210000001127 pigmented epithelial cell Anatomy 0.000 description 11
- 230000002062 proliferating effect Effects 0.000 description 11
- 239000002356 single layer Substances 0.000 description 11
- 206010064930 age-related macular degeneration Diseases 0.000 description 10
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 10
- 230000000007 visual effect Effects 0.000 description 10
- 101000670189 Homo sapiens Ribulose-phosphate 3-epimerase Proteins 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 210000000981 epithelium Anatomy 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 210000000130 stem cell Anatomy 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 8
- 108010010803 Gelatin Proteins 0.000 description 8
- 208000018737 Parkinson disease Diseases 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000008273 gelatin Substances 0.000 description 8
- 229920000159 gelatin Polymers 0.000 description 8
- 235000019322 gelatine Nutrition 0.000 description 8
- 235000011852 gelatine desserts Nutrition 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000007774 longterm Effects 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 7
- 238000004115 adherent culture Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 6
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 210000002257 embryonic structure Anatomy 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 230000004438 eyesight Effects 0.000 description 6
- 230000001605 fetal effect Effects 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 210000000554 iris Anatomy 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 235000019155 vitamin A Nutrition 0.000 description 6
- 239000011719 vitamin A Substances 0.000 description 6
- 229940045997 vitamin a Drugs 0.000 description 6
- 201000004569 Blindness Diseases 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 206010057249 Phagocytosis Diseases 0.000 description 5
- -1 RPE-65 Proteins 0.000 description 5
- 230000001464 adherent effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000011223 gene expression profiling Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000005157 neural retina Anatomy 0.000 description 5
- 230000008782 phagocytosis Effects 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 101100351026 Drosophila melanogaster ey gene Proteins 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000017442 Retinal disease Diseases 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- 206010052779 Transplant rejections Diseases 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 210000003050 axon Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000013532 laser treatment Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000004807 localization Effects 0.000 description 4
- 210000000472 morula Anatomy 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 210000000608 photoreceptor cell Anatomy 0.000 description 4
- 210000001316 polygonal cell Anatomy 0.000 description 4
- 210000001082 somatic cell Anatomy 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001585 trabecular meshwork Anatomy 0.000 description 4
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 3
- 101150034941 AURKB gene Proteins 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 3
- 206010058314 Dysplasia Diseases 0.000 description 3
- 208000003098 Ganglion Cysts Diseases 0.000 description 3
- 108010085895 Laminin Proteins 0.000 description 3
- 102000007547 Laminin Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 108060007030 Ribulose-phosphate 3-epimerase Proteins 0.000 description 3
- 102100039270 Ribulose-phosphate 3-epimerase Human genes 0.000 description 3
- 208000005400 Synovial Cyst Diseases 0.000 description 3
- 206010043276 Teratoma Diseases 0.000 description 3
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000001109 blastomere Anatomy 0.000 description 3
- 239000001058 brown pigment Substances 0.000 description 3
- 210000001775 bruch membrane Anatomy 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 210000003981 ectoderm Anatomy 0.000 description 3
- 210000002308 embryonic cell Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000004373 eye development Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000006884 regulation of angiogenesis Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108091006106 transcriptional activators Proteins 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- 102100032982 CCR4-NOT transcription complex subunit 9 Human genes 0.000 description 2
- 101150032562 CNOT9 gene Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001073422 Homo sapiens Pigment epithelium-derived factor Proteins 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 208000035719 Maculopathy Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 239000012901 Milli-Q water Substances 0.000 description 2
- 101100350582 Mus musculus Otx2 gene Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 101710131036 Opsin-1 Proteins 0.000 description 2
- 102100032646 Opsin-5 Human genes 0.000 description 2
- 101710131039 Opsin-5 Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010032788 PAX6 Transcription Factor Proteins 0.000 description 2
- 239000012807 PCR reagent Substances 0.000 description 2
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 2
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- 108090000820 Rhodopsin Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 108010017842 Telomerase Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000006727 cell loss Effects 0.000 description 2
- 210000003161 choroid Anatomy 0.000 description 2
- 230000008045 co-localization Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000011544 gradient gel Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000001153 interneuron Anatomy 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004264 retinal detachment Effects 0.000 description 2
- 150000004492 retinoid derivatives Chemical class 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 101150051888 vsx2 gene Proteins 0.000 description 2
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000036443 AIPL1-related retinopathy Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000005598 Angioid Streaks Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 101150061927 BMP2 gene Proteins 0.000 description 1
- 102100022794 Bestrophin-1 Human genes 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100161935 Caenorhabditis elegans act-4 gene Proteins 0.000 description 1
- 101100465387 Caenorhabditis elegans pas-6 gene Proteins 0.000 description 1
- 241000252229 Carassius auratus Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 206010007747 Cataract congenital Diseases 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 101100276976 Drosophila melanogaster Drak gene Proteins 0.000 description 1
- 101100295848 Drosophila melanogaster Optix gene Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102100038353 Gremlin-2 Human genes 0.000 description 1
- 241000288105 Grus Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 101000903449 Homo sapiens Bestrophin-1 Proteins 0.000 description 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
- 101001032861 Homo sapiens Gremlin-2 Proteins 0.000 description 1
- 101000835745 Homo sapiens Teratocarcinoma-derived growth factor 1 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100023967 Keratin, type I cytoskeletal 12 Human genes 0.000 description 1
- 108010065086 Keratin-12 Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101500028890 Mus musculus Neurotensin Proteins 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 102100040826 Photoreceptor disk component PRCD Human genes 0.000 description 1
- 101710089989 Photoreceptor disk component PRCD Proteins 0.000 description 1
- 208000034461 Progressive cone dystrophy Diseases 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 208000014139 Retinal vascular disease Diseases 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 108700010572 Sine oculis homeobox homolog 3 Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000027073 Stargardt disease Diseases 0.000 description 1
- 102100026404 Teratocarcinoma-derived growth factor 1 Human genes 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
- 206010045178 Tunnel vision Diseases 0.000 description 1
- 208000013521 Visual disease Diseases 0.000 description 1
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 101150067309 bmp4 gene Proteins 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 239000007978 cacodylate buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 201000008615 cone dystrophy Diseases 0.000 description 1
- 201000006754 cone-rod dystrophy Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012792 core layer Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000037416 cystogenesis Effects 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 208000001309 degenerative myopia Diseases 0.000 description 1
- 230000004340 degenerative myopia Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000017532 inherited retinal dystrophy Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 230000010311 mammalian development Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 231100001223 noncarcinogenic Toxicity 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000008186 parthenogenesis Effects 0.000 description 1
- 230000001776 parthenogenetic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000004491 retinal development Effects 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 208000026726 vitreous disease Diseases 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/062—Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Analytical Chemistry (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/041,382 US7794704B2 (en) | 2004-01-23 | 2005-01-24 | Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration |
| PCT/US2005/025860 WO2006080952A2 (en) | 2005-01-24 | 2005-07-20 | Improved modalities for the treatment of degenerative diseases of the retina |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011208002A Division JP2012024100A (ja) | 2005-01-24 | 2011-09-22 | 網膜の変性疾患の処置のための改良されたモーダリティー |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2008530984A true JP2008530984A (ja) | 2008-08-14 |
Family
ID=36740924
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007552111A Pending JP2008530984A (ja) | 2005-01-24 | 2005-07-20 | 網膜の変性疾患の処置のための改良されたモーダリティー |
| JP2011208002A Withdrawn JP2012024100A (ja) | 2005-01-24 | 2011-09-22 | 網膜の変性疾患の処置のための改良されたモーダリティー |
| JP2015026016A Pending JP2015091272A (ja) | 2005-01-24 | 2015-02-13 | 網膜の変性疾患の処置のための改良されたモーダリティー |
| JP2017080926A Pending JP2017131240A (ja) | 2005-01-24 | 2017-03-28 | 網膜の変性疾患の処置のための改良されたモーダリティー |
| JP2019149952A Pending JP2019205476A (ja) | 2005-01-24 | 2019-08-19 | 網膜の変性疾患の処置のための改良されたモーダリティー |
| JP2021135753A Pending JP2021191290A (ja) | 2005-01-24 | 2021-08-23 | 網膜の変性疾患の処置のための改良されたモーダリティー |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011208002A Withdrawn JP2012024100A (ja) | 2005-01-24 | 2011-09-22 | 網膜の変性疾患の処置のための改良されたモーダリティー |
| JP2015026016A Pending JP2015091272A (ja) | 2005-01-24 | 2015-02-13 | 網膜の変性疾患の処置のための改良されたモーダリティー |
| JP2017080926A Pending JP2017131240A (ja) | 2005-01-24 | 2017-03-28 | 網膜の変性疾患の処置のための改良されたモーダリティー |
| JP2019149952A Pending JP2019205476A (ja) | 2005-01-24 | 2019-08-19 | 網膜の変性疾患の処置のための改良されたモーダリティー |
| JP2021135753A Pending JP2021191290A (ja) | 2005-01-24 | 2021-08-23 | 網膜の変性疾患の処置のための改良されたモーダリティー |
Country Status (7)
| Country | Link |
|---|---|
| US (12) | US7794704B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2479262A1 (cg-RX-API-DMAC7.html) |
| JP (6) | JP2008530984A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005325753B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2596227A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1215960A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006080952A2 (cg-RX-API-DMAC7.html) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015091272A (ja) * | 2005-01-24 | 2015-05-14 | オカタ セラピューティクス， インコーポレイテッド | 網膜の変性疾患の処置のための改良されたモーダリティー |
| WO2015125941A1 (ja) * | 2014-02-21 | 2015-08-27 | 株式会社ヘリオス | 眼疾患治療剤、そのスクリーニング方法または網膜色素上皮細胞移植に伴う拒絶反応の予測方法 |
| JP2022095696A (ja) * | 2010-07-23 | 2022-06-28 | アステラス インスティテュート フォー リジェネレイティブ メディシン | 細胞の稀少なサブ集団を検出するための方法及び細胞の高度に精製された組成物 |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201912182UA (en) * | 2004-01-23 | 2020-02-27 | Astellas Inst For Regenerative Medicine | Improved modalities for the treatment of degenerative diseases of the retina |
| CA3015835A1 (en) | 2004-11-04 | 2006-05-18 | Astellas Institute For Regenerative Medicine | Derivation of embryonic stem cells |
| US7893315B2 (en) | 2004-11-04 | 2011-02-22 | Advanced Cell Technology, Inc. | Derivation of embryonic stem cells and embryo-derived cells |
| AU2007248412A1 (en) | 2006-05-03 | 2007-11-15 | Advanced Cell Technology, Inc. | Derivation of embryonic stem cells and embryo-derived cells |
| EP2121902A4 (en) | 2007-02-23 | 2010-12-22 | Advanced Cell Tech Inc | HIGHLY EFFICIENT METHODS OF RENEWING DIFFERENTIATED CELLS AND GENERATING ANIMALS AND EMBRYONIC STEM CELLS FROM NEWLY PROGRAMMED CELLS |
| JP5395058B2 (ja) * | 2007-04-18 | 2014-01-22 | ハダシット メディカル リサーチ サーヴィシーズ アンド ディヴェロップメント リミテッド | 幹細胞に由来する網膜色素上皮細胞 |
| US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
| CA2695225C (en) | 2007-07-31 | 2021-06-01 | Lifescan, Inc. | Differentiation of human embryonic stem cells to pancreatic endocrine |
| CA3177952A1 (en) * | 2007-10-12 | 2009-04-23 | Astellas Institute For Regenerative Medicine | Improved methods of producing rpe cells and compositions of rpe cells |
| AU2015201435B2 (en) * | 2007-10-12 | 2017-02-02 | Astellas Institute For Regenerative Medicine | Improved methods of producing RPE cells and compositions of RPE cells |
| CA2954431C (en) | 2007-11-27 | 2021-08-24 | Lifescan, Inc. | Differentiation of human embryonic stem cells to pancreatic cells |
| CN102046779A (zh) | 2008-02-21 | 2011-05-04 | 森托科尔奥索生物科技公司 | 用于细胞粘附、培养和分离的方法、表面改性培养板和组合物 |
| CA2721952C (en) * | 2008-04-22 | 2019-11-12 | Regenerative Research Foundation | Retinal pigment epithelial stem cells |
| EP2942392B1 (en) | 2008-06-30 | 2018-10-03 | Janssen Biotech, Inc. | Differentiation of pluripotent stem cells |
| ES2727950T3 (es) | 2008-10-31 | 2019-10-21 | Janssen Biotech Inc | Diferenciación de células madre embrionarias humanas en linaje endocrino pancreático |
| MX2011004565A (es) | 2008-10-31 | 2011-07-28 | Centocor Ortho Biotech Inc | Diferenciacion de celulas madre embrionarias humanas al linaje endocrino pancreatico. |
| KR101774546B1 (ko) | 2008-11-20 | 2017-09-04 | 얀센 바이오테크 인코포레이티드 | 마이크로-캐리어 상의 만능 줄기 세포 배양 |
| JP5719305B2 (ja) | 2008-11-20 | 2015-05-13 | ヤンセン バイオテツク，インコーポレーテツド | 平面支持体上での細胞付着及び培養のための方法及び組成物 |
| BR112012001480A2 (pt) | 2009-07-20 | 2015-09-01 | Janssen Biotech Inc | Diferenciação de células-tronco embriônicas humanas |
| CA3066806C (en) | 2009-08-24 | 2023-03-07 | David M. Gamm | Substantially pure human retinal progenitor, forebrain progenitor, and retinal pigment epithelium cell cultures and methods of making the same |
| WO2011063005A2 (en) * | 2009-11-17 | 2011-05-26 | Advanced Cell Technology, Inc. | Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells |
| MX343786B (es) | 2009-12-23 | 2016-11-22 | Janssen Biotech Inc | Diferenciacion de celulas madre embrionarias humanas. |
| WO2017120461A1 (en) | 2016-01-08 | 2017-07-13 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| US20130040844A1 (en) * | 2010-01-28 | 2013-02-14 | The Board Of Trustees Of The Leland Stanford Junior University | Biomarkers of aging for detection and treatment of disorders |
| US20160208011A1 (en) | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| SG10201501503VA (en) | 2010-03-01 | 2015-04-29 | Janssen Biotech Inc | Methods for purifying cells derived from pluripotent stem cells |
| EP3498825A1 (en) | 2010-05-12 | 2019-06-19 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| EP3549617B1 (en) | 2010-07-12 | 2023-09-13 | University of Southern California | Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same |
| WO2012149480A2 (en) * | 2011-04-29 | 2012-11-01 | University Of Southern California | Systems and methods for in vitro and in vivo imaging of cells on a substrate |
| CA2809300A1 (en) | 2010-08-31 | 2012-03-08 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| EP3211070A1 (en) | 2010-08-31 | 2017-08-30 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| ES2585028T3 (es) | 2010-08-31 | 2016-10-03 | Janssen Biotech, Inc. | Diferenciación de células madre pluripotentes |
| US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
| US10478206B2 (en) | 2011-04-29 | 2019-11-19 | University Of Southern California | Instruments and methods for the implantation of cell-seeded substrates |
| US8877489B2 (en) | 2011-12-05 | 2014-11-04 | California Institute Of Technology | Ultrathin parylene-C semipermeable membranes for biomedical applications |
| HUE044778T2 (hu) | 2011-11-14 | 2019-11-28 | Astellas Inst For Regenerative Medicine | Humán RPE sejt gyógyászati készítmények és alkalmazásaik |
| US8961956B2 (en) | 2011-11-30 | 2015-02-24 | Ocata Therapeutics, Inc. | Mesenchymal stromal cells and uses related thereto |
| CN104136034B (zh) | 2011-11-30 | 2018-04-24 | 安斯泰来再生医药协会 | 间充质基质细胞及其相关用途 |
| US9248013B2 (en) | 2011-12-05 | 2016-02-02 | California Institute Of Technology | 3-Dimensional parylene scaffold cage |
| MX2014007744A (es) | 2011-12-22 | 2015-01-12 | Janssen Biotech Inc | Diferenciacion de celulas madre embrionicas humanas en celulas individuales positivas de insulina hormonal. |
| MX354775B (es) | 2012-03-07 | 2018-03-20 | Janssen Biotech Inc | Medios definidos para la expansion y el mantenimiento de celulas madre pluripotentes. |
| DK3450542T3 (da) | 2012-06-08 | 2021-11-01 | Janssen Biotech Inc | Differentiering af humane embryonale stamceller til endokrine pancreatiske celler |
| CN104471059B (zh) | 2012-07-12 | 2018-04-17 | 珠海横琴爱姆斯坦生物科技有限公司 | 人胚胎干细胞衍生的间充质样干细胞、方法及其应用 |
| ES2942484T3 (es) | 2012-12-31 | 2023-06-01 | Janssen Biotech Inc | Diferenciación de células madre embrionarias humanas en células endocrinas pancreáticas usando reguladores de HB9 |
| RU2687379C2 (ru) | 2012-12-31 | 2019-05-13 | Янссен Байотек, Инк. | Суспендирование и кластеризация плюрипотентных клеток человека с целью их дифференцировки в панкреатические эндокринные клетки |
| US10344264B2 (en) | 2012-12-31 | 2019-07-09 | Janssen Biotech, Inc. | Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells |
| US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
| EP4292600A3 (en) | 2013-03-15 | 2024-04-10 | Astellas Institute for Regenerative Medicine | Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells |
| US11763070B2 (en) | 2013-03-15 | 2023-09-19 | PowerNotes LLC | Method and system for labeling and organizing data for summarizing and referencing content via a communication network |
| US11241460B2 (en) | 2013-03-15 | 2022-02-08 | Astellas Institute For Regenerative Medicine | Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells |
| EA035336B1 (ru) | 2013-12-09 | 2020-05-29 | Зе Боард Оф Трастиз Оф Зе Леланд Стэнфорд Джуниор Юниверсити | Способ лечения связанного со старением когнитивного расстройства или заболевания |
| US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
| JP6588969B2 (ja) | 2014-05-16 | 2019-10-09 | ヤンセン バイオテツク，インコーポレーテツド | 膵内分泌細胞内のｍａｆａ発現を強化するための小分子の使用 |
| EP3240890B1 (en) | 2014-12-30 | 2021-06-16 | Cell Cure Neurosciences Ltd. | Assessing retinal pigment epithelial cell populations |
| IL273405B2 (en) | 2014-12-30 | 2024-01-01 | Cell Cure Neurosciences Ltd | Rpe cell populations and methods of generating same |
| EP3108891B1 (en) * | 2015-02-20 | 2021-01-06 | Sumitomo Dainippon Pharma Co., Ltd. | Eye disease treatment agent, screening method therefor, and method for predicting rejection response associated with retinal pigment epithelial cell transplant |
| IL303401A (en) | 2015-03-23 | 2023-08-01 | Astellas Inst For Regenerative Medicine | Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors |
| EP4014984A1 (en) | 2015-06-15 | 2022-06-22 | The Board of Trustees of the Leland Stanford Junior University | Compositions for use in treating aging-associated conditions |
| SG10201913250SA (en) | 2015-08-18 | 2020-03-30 | Astellas Inst For Regenerative Medicine | Clinical formulations |
| CN108291206B (zh) | 2015-09-08 | 2022-07-08 | 富士胶片细胞动力公司 | 干细胞来源的视网膜色素上皮的基于macs的纯化 |
| AU2016321170B2 (en) | 2015-09-08 | 2022-09-01 | Fujifilm Cellular Dynamics | Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells |
| CN108350429B (zh) | 2015-10-20 | 2022-02-25 | 富士胶片细胞动力公司 | 用于将多能干细胞定向分化为免疫细胞的方法 |
| MA45479A (fr) | 2016-04-14 | 2019-02-20 | Janssen Biotech Inc | Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen |
| CN107345219A (zh) * | 2016-05-04 | 2017-11-14 | 上海米洋杨生物科技有限公司 | 一种构建验证视网膜感光细胞特异性表面蛋白的方法 |
| KR102668891B1 (ko) | 2017-04-18 | 2024-05-29 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | 항원-특이적 면역 이펙터 세포 |
| CA3137528A1 (en) | 2019-04-26 | 2020-10-29 | Riken | Composite including neural retina, retinal pigment epithelial cells, and hydrogel, and method for producing same |
| IL292610A (en) | 2019-10-30 | 2022-07-01 | Astellas Inst For Regenerative Medicine | Methods for producing retinal pigment epithelium cells |
| CN111979195B (zh) * | 2020-09-04 | 2023-06-02 | 四川大学华西医院 | 糖尿病视网膜病变全视网膜体外培养模型的构建方法 |
| CN112970666B (zh) * | 2021-02-04 | 2023-02-03 | 复旦大学附属眼耳鼻喉科医院 | 一种简便式动物近视诱导装置及制作方法 |
| JPWO2022191216A1 (cg-RX-API-DMAC7.html) | 2021-03-09 | 2022-09-15 | ||
| TW202330906A (zh) | 2021-11-19 | 2023-08-01 | 國立研究開發法人理化學研究所 | 片狀視網膜組織之製造方法 |
| CA3254454A1 (en) | 2022-03-16 | 2025-03-04 | Racthera Co., Ltd. | METHOD OF TRANSPLANTATION |
| EP4659755A1 (en) | 2023-02-14 | 2025-12-10 | RACTHERA Co., Ltd. | Therapeutic drug for retinal pigment epithelium tears |
| CN116918764B (zh) * | 2023-08-28 | 2025-11-28 | 河南省儿童医院郑州儿童医院 | 一种豚鼠近视模型的构建方法 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE196923T1 (de) | 1993-04-30 | 2000-10-15 | Photogenesis Inc | Transplantation des retinalen pigmentepithels |
| US6878544B2 (en) | 1996-04-19 | 2005-04-12 | Neurotech Sa | Retinal cell lines with extended life-span and their applications |
| GB9608145D0 (en) | 1996-04-19 | 1996-06-26 | British Tech Group | Wound healing |
| US20040086494A1 (en) | 1996-10-07 | 2004-05-06 | John Constance Mary | Immune privileged cells for delivery of proteins and peptides |
| WO1998030679A1 (en) | 1997-01-10 | 1998-07-16 | Life Technologies, Inc. | Embryonic stem cell serum replacement |
| EP1044024A1 (en) | 1998-01-02 | 2000-10-18 | Titan Pharmaceuticals, Inc. | Use of pigmented retinal epithelial cells for creation of an immune privilege site |
| EP1066368A4 (en) | 1998-03-02 | 2002-08-21 | Compucyte Corp | SELECTIVE CELL ANALYSIS |
| US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| NZ518365A (en) | 1999-10-28 | 2004-04-30 | Univ Massachusetts | Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
| JP2003533976A (ja) | 2000-01-07 | 2003-11-18 | オレゴン ヘルス アンド サイエンス ユニバーシティ | 胚分割による霊長類子孫のクローン性増殖 |
| US6602711B1 (en) | 2000-02-21 | 2003-08-05 | Wisconsin Alumni Research Foundation | Method of making embryoid bodies from primate embryonic stem cells |
| US6458589B1 (en) | 2000-04-27 | 2002-10-01 | Geron Corporation | Hepatocyte lineage cells derived from pluripotent stem cells |
| AU2001284160A1 (en) | 2000-08-19 | 2002-03-04 | Axordia Limited | Modulation of stem cell differentiation |
| US6576464B2 (en) | 2000-11-27 | 2003-06-10 | Geron Corporation | Methods for providing differentiated stem cells |
| JP2004514702A (ja) | 2000-11-29 | 2004-05-20 | オキュレックス ファーマシューティカルズ， インコーポレイテッド | 眼における移植拒絶を予防するための眼内インプラント |
| DE10108412B4 (de) | 2001-02-21 | 2006-03-09 | Cevec Pharmaceuticals Gmbh | Pigmentepithelzelle des Auges, ihre Herstellung und Verwendung in der Therapie einer Augen- oder Nervenerkrankung |
| JP2004531262A (ja) | 2001-05-15 | 2004-10-14 | ラッパポート ファミリー インスチチュート フォア リサーチ イン ザ メディカル サイエンシズ | ヒト胚性幹細胞由来インスリン産生細胞 |
| KR101073411B1 (ko) | 2001-07-12 | 2011-10-17 | 제론 코포레이션 | 인간 다분화능 줄기 세포로부터 제조된 심근 세포 계통의 세포 |
| MXPA04005010A (es) | 2001-11-26 | 2005-04-08 | Advanced Cell Tech Inc | METODO PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS METODOS PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS HUMANOS REPROGRAMADOS Y CELULAS DEL TALLO HUMANAS AUTOLOGAS E ISOGENICAS. |
| JP2005519881A (ja) | 2001-12-11 | 2005-07-07 | ファイブローゲン、インコーポレーテッド | 眼プロセスの抑制方法 |
| CA2482903A1 (en) | 2002-04-18 | 2003-10-23 | Lynkeus Biotech Gmbh | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
| US7422736B2 (en) | 2002-07-26 | 2008-09-09 | Food Industry Research And Development Institute | Somatic pluripotent cells |
| AU2003279132A1 (en) | 2002-10-04 | 2004-05-04 | Tissuetech, Inc. | Retinal pigment epithelial cell cultures on amniotic membrane and transplantation |
| AU2003302020B2 (en) | 2002-11-14 | 2008-01-31 | Ethicon Endo-Surgery, Inc. | Methods and devices for detecting tissue cells |
| CN101044404A (zh) | 2003-03-03 | 2007-09-26 | 长冈实业株式会社 | 用于不同类型细胞检测和定量的方法和装置以及生物光盘在该检测和定量中的应用 |
| SG10201912182UA (en) | 2004-01-23 | 2020-02-27 | Astellas Inst For Regenerative Medicine | Improved modalities for the treatment of degenerative diseases of the retina |
| US7794704B2 (en) | 2004-01-23 | 2010-09-14 | Advanced Cell Technology, Inc. | Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration |
| CA3015835A1 (en) | 2004-11-04 | 2006-05-18 | Astellas Institute For Regenerative Medicine | Derivation of embryonic stem cells |
| EP2048227B1 (en) | 2005-02-11 | 2015-08-19 | Agency For Science, Technology And Research | Methods for proliferating stem cells |
| KR100832592B1 (ko) | 2006-08-17 | 2008-05-27 | 박현숙 | 폴리머 막을 이용한 줄기세포와 피더세포의 공배양방법 |
| JP5395058B2 (ja) | 2007-04-18 | 2014-01-22 | ハダシット メディカル リサーチ サーヴィシーズ アンド ディヴェロップメント リミテッド | 幹細胞に由来する網膜色素上皮細胞 |
| JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| CA3177952A1 (en) | 2007-10-12 | 2009-04-23 | Astellas Institute For Regenerative Medicine | Improved methods of producing rpe cells and compositions of rpe cells |
| HU0700675D0 (en) | 2007-10-15 | 2007-12-28 | Mta Tamogatott Kutatohelyek Ir | Method for monitoring stem cell differentiation |
| US20090233324A1 (en) | 2008-03-11 | 2009-09-17 | Kopf-Sill Anne R | Methods for Diagnosing Cancer Using Samples Collected From A Central Vein Location or an Arterial Location |
| US8652123B2 (en) | 2008-09-02 | 2014-02-18 | Geoffrey C. GURTNER | Methods and devices for improving the appearance of tissue |
| WO2011063005A2 (en) | 2009-11-17 | 2011-05-26 | Advanced Cell Technology, Inc. | Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells |
| EP4524568A3 (en) | 2010-07-23 | 2025-06-18 | Astellas Institute for Regenerative Medicine | Methods for detection of rare subpopulations of cells and highly purified compositions of cells |
| WO2012149484A2 (en) | 2011-04-29 | 2012-11-01 | University Of Southern California | Method of cryopreservation of stem cell-derived retinal pigment epithelial cells on polymeric substrate |
| HUE044778T2 (hu) | 2011-11-14 | 2019-11-28 | Astellas Inst For Regenerative Medicine | Humán RPE sejt gyógyászati készítmények és alkalmazásaik |
| US9850463B2 (en) | 2012-02-01 | 2017-12-26 | The Regents Of The University Of California | Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation |
| ES2688019T3 (es) | 2012-06-05 | 2018-10-30 | The Regents Of The University Of California | Métodos y composiciones para la producción acelerada de células epiteliales pigmentadas retinianas a partir de células pluripotentes |
-
2005
- 2005-01-24 US US11/041,382 patent/US7794704B2/en active Active
- 2005-07-20 CA CA002596227A patent/CA2596227A1/en active Pending
- 2005-07-20 AU AU2005325753A patent/AU2005325753B2/en not_active Expired
- 2005-07-20 JP JP2007552111A patent/JP2008530984A/ja active Pending
- 2005-07-20 WO PCT/US2005/025860 patent/WO2006080952A2/en not_active Ceased
- 2005-07-20 EP EP12159755A patent/EP2479262A1/en not_active Withdrawn
- 2005-07-20 EP EP15248004.2A patent/EP2927314A1/en not_active Withdrawn
- 2005-07-20 EP EP05773674A patent/EP1850658A4/en not_active Withdrawn
-
2010
- 2010-08-17 US US12/857,911 patent/US8268303B2/en not_active Expired - Lifetime
-
2011
- 2011-09-22 JP JP2011208002A patent/JP2012024100A/ja not_active Withdrawn
-
2012
- 2012-05-22 US US13/477,763 patent/US9080150B2/en not_active Expired - Lifetime
-
2013
- 2013-04-08 US US13/858,534 patent/US9040038B2/en not_active Expired - Lifetime
- 2013-04-08 US US13/858,497 patent/US9045732B2/en not_active Expired - Lifetime
- 2013-04-08 US US13/858,376 patent/US9650607B2/en not_active Expired - Lifetime
- 2013-04-08 US US13/858,354 patent/US9562217B2/en not_active Expired - Lifetime
- 2013-04-18 US US13/865,751 patent/US9040039B2/en not_active Expired - Lifetime
-
2014
- 2014-03-27 US US14/227,305 patent/US9193950B2/en not_active Expired - Lifetime
- 2014-03-27 US US14/227,237 patent/US9181524B2/en not_active Expired - Lifetime
-
2015
- 2015-02-13 JP JP2015026016A patent/JP2015091272A/ja active Pending
-
2016
- 2016-04-06 HK HK16103910.3A patent/HK1215960A1/en unknown
-
2017
- 2017-03-28 JP JP2017080926A patent/JP2017131240A/ja active Pending
- 2017-04-24 US US15/495,917 patent/US20180023052A1/en not_active Abandoned
-
2019
- 2019-08-19 JP JP2019149952A patent/JP2019205476A/ja active Pending
-
2020
- 2020-05-19 US US16/878,485 patent/US20210102164A1/en not_active Abandoned
-
2021
- 2021-08-23 JP JP2021135753A patent/JP2021191290A/ja active Pending
Non-Patent Citations (1)
| Title |
|---|
| JPN7011000961; Ｃｌｏｎｉｎｇ ａｎｄ Ｓｔｅｍ Ｃｅｌｌｓ（２００４），Ｖｏｌ．６，Ｎｏ．３，ｐ．２１７-２４５ * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015091272A (ja) * | 2005-01-24 | 2015-05-14 | オカタ セラピューティクス， インコーポレイテッド | 網膜の変性疾患の処置のための改良されたモーダリティー |
| JP2022095696A (ja) * | 2010-07-23 | 2022-06-28 | アステラス インスティテュート フォー リジェネレイティブ メディシン | 細胞の稀少なサブ集団を検出するための方法及び細胞の高度に精製された組成物 |
| JP7412470B2 (ja) | 2010-07-23 | 2024-01-12 | アステラス インスティテュート フォー リジェネレイティブ メディシン | 細胞の稀少なサブ集団を検出するための方法及び細胞の高度に精製された組成物 |
| WO2015125941A1 (ja) * | 2014-02-21 | 2015-08-27 | 株式会社ヘリオス | 眼疾患治療剤、そのスクリーニング方法または網膜色素上皮細胞移植に伴う拒絶反応の予測方法 |
| KR20160116008A (ko) * | 2014-02-21 | 2016-10-06 | 가부시키가이샤 헤리오스 | 눈 질환 치료제, 이의 스크리닝 방법, 및 망막 색소 상피 세포 이식과 연관된 거부 반응의 예측 방법 |
| JPWO2015125941A1 (ja) * | 2014-02-21 | 2017-03-30 | 株式会社ヘリオス | 眼疾患治療剤、そのスクリーニング方法または網膜色素上皮細胞移植に伴う拒絶反応の予測方法 |
| US10240201B2 (en) | 2014-02-21 | 2019-03-26 | Healios K.K. | Eye disease treatment agent, screening method therefor, and method for predicting rejection response associated with retinal pigment epithelial cell transplant |
| JP2020055796A (ja) * | 2014-02-21 | 2020-04-09 | 大日本住友製薬株式会社 | 眼疾患治療剤、そのスクリーニング方法または網膜色素上皮細胞移植に伴う拒絶反応の予測方法 |
| KR102354410B1 (ko) | 2014-02-21 | 2022-01-21 | 다이니뽄 스미토모 세이야쿠 가부시키가이샤 | 눈 질환 치료제, 이의 스크리닝 방법, 및 망막 색소 상피 세포 이식과 연관된 거부 반응의 예측 방법 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019205476A (ja) | 網膜の変性疾患の処置のための改良されたモーダリティー | |
| US9730962B2 (en) | Modalities for the treatment of degenerative diseases of the retina | |
| JP2015091272A5 (cg-RX-API-DMAC7.html) | ||
| US20240226176A9 (en) | Modalities for the treatment of degenerative diseases of the retina | |
| AU2021200383A1 (en) | Improved modalities for the treatment of degenerative diseases of the retina | |
| AU2012201562B2 (en) | Improved modalities for the treatment of degenerative diseases of the retina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080717 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110322 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110621 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110628 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110721 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110725 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110728 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110802 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110922 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120516 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120815 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120822 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120914 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120924 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121015 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121022 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121116 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20121116 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130218 |